About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a company based in Boston (United States) founded in 1996 was acquired by Paratek Pharma in July 2014.. Transcept Pharmaceuticals has raised $40 million across 2 funding rounds from investors including Hercules Capital, Paratek Pharma and New Leaf Venture Partners. Transcept Pharmaceuticals has completed 1 acquisition, including Novacea. Transcept Pharmaceuticals operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Boston, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Transcept Pharmaceuticals, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$40 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series D
Mar 01, 2007
-
Investors
Hercules Capital
& 8 more
-
Employee Count
Employee Count
- Investments & Acquisitions
-
Acquired by
Paratek Pharma
(Jul 01, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Transcept Pharmaceuticals
Transcept Pharmaceuticals has successfully raised a total of $40M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $40 million completed in March 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series D — $40.0M
- First Round First Round
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2007 | Amount | Series D - Transcept Pharmaceuticals | Valuation |
investors |
|
| Jun, 2001 | Amount | Series A - Transcept Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Transcept Pharmaceuticals
Transcept Pharmaceuticals has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include Hercules Capital, Paratek Pharma and New Leaf Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Transcept Pharmaceuticals
Transcept Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Novacea. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Serotonin inhibitor drugs for cancer are developed by Novacea.
|
2001 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Transcept Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Transcept Pharmaceuticals Comparisons
Competitors of Transcept Pharmaceuticals
Transcept Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| domain | founded_year | HQ Location |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Transcept Pharmaceuticals
Frequently Asked Questions about Transcept Pharmaceuticals
When was Transcept Pharmaceuticals founded?
Transcept Pharmaceuticals was founded in 1996 and raised its 1st funding round 5 years after it was founded.
Where is Transcept Pharmaceuticals located?
Transcept Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Transcept Pharmaceuticals a funded company?
Transcept Pharmaceuticals is a funded company, having raised a total of $40M across 2 funding rounds to date.
What does Transcept Pharmaceuticals do?
Paratek is focused on the discovery, development, and commercialization of medicines that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Lead product candidate, omadacycline (phase 3), is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections. It is also developing sacrecycline (phase 3) for acne in partnership with Allergan. Other pipeline compounds include 2 molecules in phase 3 for acquired bacterial pneumonia infections and skin structure infections.
Who are the top competitors of Transcept Pharmaceuticals?
Transcept Pharmaceuticals's top competitors include Insmed, MaaT Pharma and Basilea.
How many acquisitions has Transcept Pharmaceuticals made?
Transcept Pharmaceuticals has made 1 acquisition, including Novacea.
Who are Transcept Pharmaceuticals's investors?
Transcept Pharmaceuticals has 9 investors. Key investors include Hercules Capital, Paratek Pharma, New Leaf Venture Partners, NEA, and InterWest.